- Home
- GIPR vs KZIA Comparison
GIPR vs KZIA Comparison
Compare GIPR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIPR | KZIA |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 161.5M |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | GIPR | KZIA |
|---|---|---|
| Price | $0.81 | $9.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 702.2K | ★ 2.0M |
| Earning Date | 11-17-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,953,920.00 | $1,199,108.00 |
| Revenue This Year | $1.12 | N/A |
| Revenue Next Year | $0.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.78 | $2.86 |
| 52 Week High | $2.06 | $21.00 |
Technical Indicators
Market Signals| Indicator | GIPR | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 47.96 |
| Support Level | $0.89 | $9.14 |
| Resistance Level | $1.34 | $17.40 |
| Average True Range (ATR) | 0.13 | 2.51 |
| MACD | 0.01 | -0.37 |
| Stochastic Oscillator | 7.27 | 23.56 |
Price Performance
Historical ComparisonAbout GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.